Displaying drugs 10651 - 10675 of 11653 in total
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive …
Eldecalcitol
Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
Investigational
Matched Description: … Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a …
Filaminast
Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Experimental
Matched Description: … Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). …
Porfiromycin
Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.
Investigational
Matched Description: … Porfiromycin is a substance that is being studied in the treatment of cancer. …
Diridavumab
Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Investigational
Matched Description: … Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics …
Swertia japonica whole flowering
Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products …
Bixalomer
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Orilanolimab
Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Investigational
Matched Description: … Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects …
Ro 24-7429
Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
Investigational
Matched Description: … Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With …
HIV Integrase Inhibitor
HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects).
Investigational
Matched Description: … HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose …
Imsidolimab
Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).
Investigational
Matched Description: … Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and …
NY-ESO-1 peptide vaccine
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Investigational
Matched Description: … It contains a peptide derived from the cancer-testis antigen (NY-ESO-1). …
FLT201
FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta (β)-glucocerebrosidase variant 85 (GCasevar85)
Investigational
Matched Description: … FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression …
Tanfanercept
Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).
Investigational
Matched Description: … Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and …
Clomocycline
Clomocycline is a tetracycline used to treat bacterial infections.
Experimental
Matched Description: … Clomocycline is a tetracycline used to treat bacterial infections. …
INCB3284
INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.
Investigational
Matched Description: … INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases. …
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
Matched Description: … A synthetic purine nucleoside analogue with potential antineoplastic activity. …
PD-169316
PD-169316 is a p38 MAP kinase inhibitor.
Investigational
Matched Description: … PD-169316 is a p38 MAP kinase inhibitor.[A253062] …
PD-173952
PD-173952 is a potent Myt1 kinase inhibitor.
Investigational
Matched Description: … PD-173952 is a potent Myt1 kinase inhibitor.[A253067] …
Tabituximab barzuxetan yttrium Y-90
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
Matched Description: … A version of [tabituximab barzuxetan] radiolabeled with yttrium-90. …
Fencamfamin
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite ... It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers …
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
CYP-001
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Matched Description: … These cells have advantage over other MSCs because a large amount can be obtained from a single healthy ... CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
HZT-501
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
Matched Description: … ., a privately held biopharmaceutical company. ... HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. …
Displaying drugs 10651 - 10675 of 11653 in total